Department of Orthopedics, Mayo Clinic, 14th Floor, Gonda Building, 200 1st Street SW, Rochester, MN 55902, USA.
Clin Orthop Relat Res. 2012 Nov;470(11):3041-7. doi: 10.1007/s11999-012-2382-8.
Pelvic radiation has been commonly used to treat gastrointestinal, genitourinary, or hematopoietic malignancies. Conventional THA in these patients reportedly have high rates of fixation failure. Although secure short-term fixation reportedly occurs with trabecular metal implants following pelvic radiation, it is unclear whether the fixation is durable.
QUESTIONS/PURPOSES: We determined the survival of trabecular metal acetabular components in patients having THA following pelvic radiation and assessed function and radiographic loosening.
We retrospectively reviewed 29 patients with prior pelvic radiation who had 34 arthroplasties using trabecular metal acetabular components from 1998 and 2005. The mean pelvic radiation dose was 6300 cGy. We collected the following data: patient demographics, surgery and implant information, clinical and radiographic followup, and tumor and radiotherapy related details. We obtained Harris hip scores (HHS) on all patients. Ten patients died of disease prior to 5 years and two patients were excluded, leaving 17 patients (22 hips) with a minimum of 5 years of clinical (mean, 78 months; median, 71; range, 57-116) and radiographic (mean, 73; median, 65; range, 51-116) followup.
All implants were in place in the surviving patients. The mean HHS improved from 36 preoperatively to 80 at latest followup. There were no reoperations for any reason, and we observed no implant loosening or migration at final followup in surviving or deceased patients.
Tantalum trabecular metal acetabular components restored function and provided durable reconstruction in patients undergoing THA following prior pelvic radiation. We observed no clinical or radiographic failures at a minimum 5-year followup.
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
盆腔放疗常用于治疗胃肠道、泌尿生殖系统或血液系统恶性肿瘤。据报道,此类患者行传统全髋关节置换术(THA)后,假体固定失败率较高。虽然据报道,盆腔放疗后使用多孔钽髋臼假体可实现短期牢固固定,但固定的耐久性尚不清楚。
问题/目的:我们旨在评估盆腔放疗后行 THA 患者多孔钽髋臼假体的生存率,并评估其功能和影像学松动情况。
我们回顾性分析了 1998 年至 2005 年期间因盆腔放疗而行多孔钽髋臼假体 THA 的 29 例患者的 34 例髋关节置换术,平均盆腔放疗剂量为 6300cGy。我们收集了以下数据:患者人口统计学资料、手术和植入物信息、临床和影像学随访情况,以及肿瘤和放疗相关细节。我们对所有患者进行了髋关节 Harris 评分(HHS)评估。10 例患者在 5 年内死于疾病,2 例患者被排除在外,最终有 17 例患者(22 髋)获得了至少 5 年的临床(平均 78 个月;中位数 71 个月;范围 57-116 个月)和影像学(平均 73 个月;中位数 65 个月;范围 51-116 个月)随访。
所有存活患者的植入物均在位。HHS 由术前的 36 分平均提高至末次随访时的 80 分。无任何原因的再次手术,在存活或死亡患者的最终随访中,均未观察到假体松动或迁移。
多孔钽髋臼假体在盆腔放疗后行 THA 的患者中恢复了功能,提供了持久的重建。在至少 5 年的随访中,我们未观察到临床或影像学失败。
IV 级,治疗性研究。欲了解完整的证据等级描述,请参见《作者指南》。